Table 2. Correlation of immunohistochemical NHLRC2 expression assessed by image analysis in lung cancer and disease-specific or overall survival.
| Lung cancer type | NHLRC2 expression | 5-year survival (%) | P value | Mean survival, months (95% CI) | Median survival, months (95% CI) | P value |
|---|---|---|---|---|---|---|
| Disease specific survival | ||||||
| Adenocarcinoma | Low (n=51) | 53.5 | 0.003 | 87.41 (68.91–195.90) | 80.00 (30.55–129.45) | 0.002 |
| High (n=51) | 26.7 | 49.24 (31.97–66.51) | 21.00 (15.52–26.48) | |||
| Squamous cell carcinoma | Low (n=54) | 46.6 | 0.156 | 80.53 (60.23–100.83) | 46.00 (1.13– 90.87) | 0.757 |
| High (n=57) | 59.2 | 73.89 (60.19–87.60) | 65.00 (44.30–85.70) | |||
| All | Low (n=105) | 50.1 | 0.461 | 81.71 (67.59–95.83) | 70.00 (40.69–99.31) | 0.348 |
| High (n=108) | 43.8 | 71.90 (57.59–86.22) | 41.00 (20.99–61.01) | |||
| Overall survival | ||||||
| Adenocarcinoma | Low (n=51) | 49.0 | <0.001 | 74.68 (58.27–91.09) | 59.00 (24.83–93.17) | 0.001 |
| High (n=51) | 21.6 | 39.31 (25.94–52.67) | 18.00 (14.12–21.88) | |||
| Squamous cell carcinoma | Low (n=54) | 36.9 | 0.355 | 65.27 (47.93–82.61) | 35.00 (21.80–48.20) | 0.590 |
| High (n=57) | 43.9 | 56.52 (45.55–67.48) | 55.00 (35.98–74.02) | |||
| All | Low (n=105) | 43.7 | 0.127 | 66.71 (55.15–78.28) | 47.00 (27.97–66.03 | 0.070 |
| High (n=108) | 32.4 | 53.36 (42.93–63.79) | 31.00 (21.60–40.40) |
CI, confidence interval; n, number; NHLRC2, NHL repeat (named after NCL-1, HT2A and LIN-41)-containing protein 2.